JP Morgan Chase’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-109
| Closed | -$812 | – | 7927 |
|
|
2026
Q1 | $812 | Hold |
109
| – | – | ﹤0.01% | 7146 |
|
|
2025
Q4 | $686 | Sell |
109
-100
| -48% | -$583 | ﹤0.01% | 7057 |
|
|
2025
Q3 | $815 | Hold |
209
| – | – | ﹤0.01% | 7002 |
|
|
2025
Q2 | $957 | Buy |
209
+43
| +26% | +$184 | ﹤0.01% | 6628 |
|
|
2025
Q1 | $810 | Sell |
166
-11,718
| -99% | -$71.1K | ﹤0.01% | 6656 |
|
|
2024
Q4 | $79.9K | Buy |
11,884
+11,717
| +7,016% | +$87.3K | ﹤0.01% | 5833 |
|
|
2024
Q3 | $1.29K | Sell |
167
-152
| -48% | -$917 | ﹤0.01% | 6692 |
|
|
2024
Q2 | $1.91K | Sell |
319
-2,727
| -90% | -$20.7K | ﹤0.01% | 6532 |
|
|
2024
Q1 | $27.5K | Sell |
3,046
-1,580
| -34% | -$14.4K | ﹤0.01% | 6138 |
|
|
2023
Q4 | $43.8K | Sell |
4,626
-91,236
| -95% | -$802K | ﹤0.01% | 6041 |
|
|
2023
Q3 | $1.14M | Sell |
95,862
-12,106
| -11% | -$215K | ﹤0.01% | 3973 |
|
|
2023
Q2 | $2.65M | Sell |
107,968
-761
| -0.7% | -$19.8K | ﹤0.01% | 3329 |
|
|
2023
Q1 | $3.4M | Buy |
108,729
+1,642
| +2% | +$95K | ﹤0.01% | 3123 |
|
|
2022
Q4 | $7.54M | Buy |
107,087
+1,312
| +1% | +$97.3K | ﹤0.01% | 2494 |
|
|
2022
Q3 | $9.11M | Sell |
105,775
-4,379
| -4% | -$425K | ﹤0.01% | 2218 |
|
|
2022
Q2 | $9.11M | Buy |
110,154
+103,775
| +1,627% | +$9.15M | ﹤0.01% | 2245 |
|
|
2022
Q1 | $1.06M | Buy |
6,379
+4,628
| +264% | +$664K | ﹤0.01% | 4222 |
|
|
2021
Q4 | $293K | Buy |
1,751
+89
| +5% | +$10K | ﹤0.01% | 5149 |
|
|
2021
Q3 | $144K | Sell |
1,662
-838
| -34% | -$55.5K | ﹤0.01% | 5394 |
|
|
2021
Q2 | $136K | Buy |
2,500
+1,322
| +112% | +$75.1K | ﹤0.01% | 5427 |
|
|
2021
Q1 | $70K | Sell |
1,178
-208
| -15% | -$12.2K | ﹤0.01% | 5462 |
|
|
2020
Q4 | $72K | Sell |
1,386
-1,250
| -47% | -$69.5K | ﹤0.01% | 5070 |
|
|
2020
Q3 | $124K | Buy |
2,636
+403
| +18% | +$19.3K | ﹤0.01% | 4596 |
|
|
2020
Q2 | $115K | Buy |
2,233
+1,232
| +123% | +$62.2K | ﹤0.01% | 4509 |
|
|
2020
Q1 | $44K | Sell |
1,001
-6,816
| -87% | -$277K | ﹤0.01% | 4764 |
|
|
2019
Q4 | $313K | Buy |
7,817
+2,492
| +47% | +$76.7K | ﹤0.01% | 4487 |
|
|
2019
Q3 | $175K | Buy |
5,325
+1,497
| +39% | +$72.3K | ﹤0.01% | 4689 |
|
|
2019
Q2 | $275K | Buy |
3,828
+3,522
| +1,151% | +$548K | ﹤0.01% | 4520 |
|
|
2019
Q1 | $54K | Buy |
306
+174
| +132% | +$34.3K | ﹤0.01% | 5101 |
|
|
2018
Q4 | $31K | Buy |
132
+13
| +11% | +$3.18K | ﹤0.01% | 5227 |
|
|
2018
Q3 | $26K | Buy |
+119
| New | +$20.8K | ﹤0.01% | 5371 |
|
JP Morgan Chase's KZR Position: Q2 2026 in Review
JP Morgan Chase sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 109 shares — an estimated $812 sold.
JP Morgan Chase first reported a position in KZR in Q3 2018 and held it in 31 quarters. The position peaked at $9.11M in Q2 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- JP Morgan Chase reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 109 Kezar Life Sciences shares in Q2 2026, an estimated $812.
- JP Morgan Chase first reported a position in Kezar Life Sciences in Q3 2018 and held it in 31 quarters.
- JP Morgan Chase's Kezar Life Sciences position peaked at $9.11M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.